ACADIA Pharmaceuticals Reports Q1 2025 Financial Results with Increased Revenue and Net Income

ACADIA Pharmaceuticals Inc. reported its financial results for the first quarter of 2025, revealing a net income of $18.99 million, or $0.11 per diluted share, compared to a net income of $16.56 million, or $0.10 per diluted share, in the same period last year. The company’s total revenues increased to $244.32 million, up from $205.83 million in the first quarter of 2024, primarily driven by higher product sales of its two key drugs, NUPLAZID and DAYBUE. NUPLAZID sales rose to $159.72 million from $129.92 million, while DAYBUE sales increased to $84.60 million from $75.91 million.

Operating expenses for the quarter totaled $225.03 million, an increase from $190.62 million in the prior year, largely due to higher research and development costs, which rose to $78.27 million from $59.68 million. Selling, general, and administrative expenses also increased to $126.37 million from $107.99 million. The company’s accumulated deficit as of March 31, 2025, stood at $2.19 billion, reflecting ongoing investments in product development and commercialization efforts.

In terms of operational developments, ACADIA has made significant strides in expanding its product offerings and market presence. The FDA approved DAYBUE in March 2023 for the treatment of Rett syndrome, and it became available for prescription in the U.S. in April 2023. Additionally, Health Canada granted marketing authorization for DAYBUE in October 2024. The company is also advancing its pipeline, with ongoing clinical trials for ACP-101 and ACP-204, targeting conditions such as hyperphagia in Prader-Willi syndrome and Alzheimer’s disease psychosis, respectively.

The company’s cash and cash equivalents decreased to $217.70 million as of March 31, 2025, down from $319.59 million at the end of 2024. This decline was attributed to cash used in operating activities and significant payments related to licensing agreements. ACADIA anticipates that its current cash reserves, along with expected product sales, will be sufficient to fund operations through the next 12 months. However, the company may require additional financing in the future to support its ongoing research and development activities and potential acquisitions.

Looking ahead, ACADIA remains focused on expanding its product portfolio and market reach while navigating the complexities of regulatory requirements and market dynamics. The company is committed to advancing its clinical programs and maintaining its competitive position in the biopharmaceutical industry, despite the challenges posed by ongoing economic uncertainties and evolving healthcare regulations.